Robeco Institutional Asset Management B.V. Has $241.06 Million Stock Holdings in Boston Scientific Corporation (NYSE:BSX)

Robeco Institutional Asset Management B.V. boosted its stake in Boston Scientific Corporation (NYSE:BSX - Free Report) by 24.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,389,578 shares of the medical equipment provider's stock after buying an additional 467,277 shares during the quarter. Robeco Institutional Asset Management B.V. owned approximately 0.16% of Boston Scientific worth $241,061,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of BSX. Parnassus Investments LLC boosted its position in shares of Boston Scientific by 0.7% during the fourth quarter. Parnassus Investments LLC now owns 14,861 shares of the medical equipment provider's stock worth $1,327,000 after buying an additional 97 shares during the period. Baldwin Investment Management LLC raised its holdings in Boston Scientific by 1.2% during the fourth quarter. Baldwin Investment Management LLC now owns 8,740 shares of the medical equipment provider's stock worth $781,000 after acquiring an additional 102 shares in the last quarter. Evergreen Capital Management LLC raised its holdings in Boston Scientific by 1.7% during the fourth quarter. Evergreen Capital Management LLC now owns 6,331 shares of the medical equipment provider's stock worth $565,000 after acquiring an additional 106 shares in the last quarter. PDS Planning Inc raised its holdings in Boston Scientific by 1.5% during the fourth quarter. PDS Planning Inc now owns 7,474 shares of the medical equipment provider's stock worth $668,000 after acquiring an additional 113 shares in the last quarter. Finally, Paladin Wealth LLC raised its holdings in Boston Scientific by 1.6% during the first quarter. Paladin Wealth LLC now owns 7,156 shares of the medical equipment provider's stock worth $722,000 after acquiring an additional 113 shares in the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Wall Street Analyst Weigh In

Several analysts recently issued reports on BSX shares. Evercore ISI upped their target price on Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a report on Thursday, April 24th. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Barclays upped their target price on Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Wall Street Zen upgraded Boston Scientific from a "hold" rating to a "buy" rating in a report on Tuesday, April 29th. Finally, Leerink Partnrs upgraded Boston Scientific to a "strong-buy" rating in a report on Monday, June 16th. Twenty-two research analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $116.09.

Insider Transactions at Boston Scientific

In related news, SVP Vance R. Brown sold 4,826 shares of the stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $95.09, for a total transaction of $458,904.34. Following the sale, the senior vice president now owns 36,193 shares of the company's stock, valued at $3,441,592.37. This represents a 11.77% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $102.48, for a total value of $16,852,118.64. Following the sale, the chief executive officer now directly owns 1,535,706 shares in the company, valued at $157,379,150.88. This represents a 9.67% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 411,970 shares of company stock worth $42,406,693. Company insiders own 0.50% of the company's stock.

Boston Scientific Stock Performance

Shares of NYSE BSX traded up $2.25 during trading hours on Friday, reaching $106.83. 15,636,958 shares of the stock were exchanged, compared to its average volume of 6,627,874. The firm has a market capitalization of $158.05 billion, a price-to-earnings ratio of 77.98, a P/E/G ratio of 2.70 and a beta of 0.68. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.88 and a current ratio of 1.45. Boston Scientific Corporation has a 52 week low of $71.88 and a 52 week high of $107.17. The stock's fifty day simple moving average is $102.51 and its 200 day simple moving average is $99.44.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. The company had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The firm's quarterly revenue was up 20.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.56 earnings per share. Sell-side analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.